MAPT P270P

MUTATIONS MAPT 44074018 GRCh37/hg19 rs11568305 G A g.110058G> A g.107232G> A Exon 9 Point, Silent Coding Unknown. Not applicable. P270P Frontotemporal Dementia: BenignNone This silent polymorphism was detected in healthy family members as well as at least one

MAPT L266L

MUTATIONS MAPT 44074006 GRCh37/hg19 G A g.110046G> A g.107220G> A Exon 9 Point, Silent Coding Unknown. Not applicable. L266L Frontotemporal Dementia: BenignNone This synonymous change was identified in one individual originating from Pakistan (Guerreiro et al

MAPT L266V

MUTATIONS MAPT 44074004 GRCh37/hg19 rs63750349 C G g.110044C> G g.107218C> G Exon 9 Point, Missense Coding Increased levels of exon 10+ tau mRNA and soluble four-repeat (4R) tau; Decreased rate and extent of tau-induced microtubule assembly; A 3R isoform-spec

PAPER Kobayashi T, Ota S, Tanaka K, Ito Y, Hasegawa M, Umeda Y, Motoi Y, Takanashi M, Yasuhara M, Anno M, Mizuno Y, Mori H

A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology.

Ann Neurol. 2003 Jan;53(1):133-7. PubMed: 12509859

Nigel Greig on Single-Blind Trial: Diabetes Drug Helps Parkinson’s, Maybe

COMMENT I view this study of exenatide as very exciting, albeit an "open" clinical trial (without placebo). This caveat is well described by the authors and in the accompanying commentary. Open clinical trials clearly have pluses (reduced expense, there

PAPER Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, Kortesmaa J, Mercer A, Nielsen E, Rönnholm H, Wikström L

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.

J Neurosci Res. 2008 Feb 1;86(2):326-38. PubMed: 17803225

PAPER Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.

J Neuroinflammation. 2008;5:19. PubMed: 18492290

PAPER Foltynie T, Kahan J

Parkinson's disease: an update on pathogenesis and treatment.

J Neurol. 2013 May;260(5):1433-40. PubMed: 23589196

Keren Soenarjo

Indonesia

Single-Blind Trial: Diabetes Drug Helps Parkinson’s, Maybe

RESEARCH NEWS 2013-06-03 Research News Could an approved diabetes medication treat Parkinson’s disease? Perhaps, according to results published online May 20 in the Journal of Clinical Investigation. Scientists led by Thomas Foltynie, University College London, U.K., report that

PAPER Reichelt AC, Killcross S, Wilkinson LS, Humby T, Good MA

Transgenic expression of the FTDP-17 tauV337M mutation in brain dissociates components of executive function in mice.

Neurobiol Learn Mem. 2013 Sep;104:73-81. PubMed: 23721814

PAPER Akizuki M, Yamashita H, Uemura K, Maruyama H, Kawakami H, Ito H, Takahashi R

Optineurin suppression causes neuronal cell death via NF-κB pathway.

J Neurochem. 2013 May 30; PubMed: 23721573

PAPER Wu LS, Cheng WC, Shen CK

Similar dose-dependence of motor neuron cell death caused by wild type human TDP-43 and mutants with ALS-associated amino acid substitutions.

J Biomed Sci. 2013;20:33. PubMed: 23721326

PAPER Towner RA, Smith N, Saunders D, Lupu F, Silasi-Mansat R, West M, Ramirez DC, Gomez-Mejiba SE, Bonini MG, Mason RP, Ehrenshaft M, Hensley K

In vivo detection of free radicals using molecular MRI and immuno-spin trapping in a mouse model for amyotrophic lateral sclerosis.

Free Radic Biol Med. 2013 Oct;63:351-60. PubMed: 23722162

PAPER Head MW, Yull HM, Ritchie DL, Langeveld JP, Fletcher NA, Knight RS, Ironside JW

Variably protease-sensitive prionopathy in the UK: a retrospective review 1991-2008.

Brain. 2013 Apr;136(Pt 4):1102-15. PubMed: 23550113